Investors Push Novo Nordisk Toward Acquisitions to Broaden Portfolio
Deep News
Yesterday
Shareholders of Novo Nordisk are urging the pharmaceutical giant to pursue acquisitions to diversify its product lineup, aiming to reduce its financial reliance on the diabetes medication Ozempic.
Eugen Uretzki, an analyst at shareholder Flossbach, noted that the development potential of Novo Nordisk's assets "has yet to be proven."
Meanwhile, Julia Angeles, an investment manager at Baillie Gifford, a Novo Nordisk investor, stated that the company must articulate a strategy for transitioning away from its dependence on Ozempic. She suggested that possible avenues could include forging partnerships to pursue additional experimental therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.